CARBILEV Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Carbilev, and what generic alternatives are available?
Carbilev is a drug marketed by Ranbaxy and is included in one NDA.
The generic ingredient in CARBILEV is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Carbilev
A generic version of CARBILEV was approved as carbidopa; levodopa by DR REDDYS LABS SA on August 28th, 1992.
Summary for CARBILEV
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 7 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | CARBILEV at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for CARBILEV
US Patents and Regulatory Information for CARBILEV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranbaxy | CARBILEV | carbidopa; levodopa | TABLET, FOR SUSPENSION;ORAL | 076643-001 | Jun 10, 2005 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Ranbaxy | CARBILEV | carbidopa; levodopa | TABLET, FOR SUSPENSION;ORAL | 076643-002 | Jun 10, 2005 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Ranbaxy | CARBILEV | carbidopa; levodopa | TABLET, FOR SUSPENSION;ORAL | 076643-003 | Jun 10, 2005 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for CARBILEV
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Amneal Pharma Europe Ltd | Numient | levodopa, carbidopa | EMEA/H/C/002611 Symptomatic treatment of adult patients with Parkinson’s disease |
Withdrawn | no | no | no | 2015-11-19 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
